66290e22-72a1-4af2-93a6-e4859f91a7ef
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.300
- ANDROGEN_RESPONSE+0.200
- BILE_ACID_METABOLISM+0.200
- HEME_METABOLISM+0.200
- PEROXISOME+0.200
- TGF_BETA_SIGNALING+0.200
- ESTROGEN_RESPONSE_EARLY+0.100
- FATTY_ACID_METABOLISM+0.100
- NOTCH_SIGNALING+0.100
- OXIDATIVE_PHOSPHORYLATION+0.100
Top 10 suppressed
- G2M_CHECKPOINT-0.300
- HYPOXIA-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- ALLOGRAFT_REJECTION-0.200
- APOPTOSIS-0.200
- DNA_REPAIR-0.200
- E2F_TARGETS-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- INFLAMMATORY_RESPONSE-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02973 | — | cohortA1 | 0.802 |
| 2 | TCGA-44-6776-01A-11R-1858-07 | — | cohortA2 | 0.799 |
| 3 | SRR8613744 | — | F | 0.780 |
| 4 | C3L-01889 | — | cohortA2 | 0.779 |
| 5 | MNG32 | — | — | 0.765 |
| 6 | TCGA-78-7633-01A-11R-2066-07 | — | cohortA2 | 0.765 |
| 7 | TCGA-86-8281-01A-11R-2287-07 | — | cohortA2 | 0.765 |
| 8 | TCGA-05-4396-01A-21R-1858-07 | — | cohortA3 | 0.756 |
| 9 | ULC0569T_S27 | — | cohortA1 | 0.744 |
| 10 | C3L-00893 | — | cohortA1 | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |